Halberd, Author at Halberd Corporation

May 28 2026

Halberd/NeuroSenseAI Reach New Vocal Data Engineering Milestone

By Halberd|2026-05-28T11:34:59-04:00May 28th, 2026|Uncategorized|0 Comments

Jackson Center, PA – May 28, 2026 – Halberd Corporation (OTC: HALB) announced today that NeuroSense AI, the behavioral intelligence platform in development by the Company, has achieved a new engineering milestone: end-to-end processing of externally supplied, long-form voice recordings—including direct-from-file ingestion, feature extraction, and automated visualization suitable for partner review and internal validation workflows. ...

Apr 27 2022

Dr. Gregg Sturrus’ TEDx Talk Features Halberd’s Extracorporeal Treatment of Neurodegenerative Diseases

By Halberd|2022-04-27T16:28:20-04:00April 27th, 2022|Medical, News, Videos|0 Comments

Jackson Center, PA, April 27, 2022 – A key member of Halberd Corporation’s (OTC PINK:HALB) Research Team, Dr. W. Gregg Sturrus, recently gave a TEDx Talk® on Halberd’s patented and patent-pending extracorporeal elimination of neurodegenerative disease proteins and cytokines using lasers and metallic nanoparticles. Dr. Sturrus, in his talk, provided a brief ...

Apr 4 2022

Halberd Continues In-Vitro Successes With Elimination of Protein Linked to Depression

By Halberd|2022-04-05T20:32:09-04:00April 4th, 2022|Investor News, Medical, News, Press Releases|Comments Off on Halberd Continues In-Vitro Successes With Elimination of Protein Linked to Depression

Jackson Center, PA, April 4, 2022 – Halberd Corporation (OTC PINK:HALB) demonstrated the extracorporeal elimination of C-Reactive Protein from cerebral spinal fluid (CSF) by exposure to tuned laser light, in vitro. Halberd, encouraged by its recent success in eliminating all ten of the top antigens associated with PTSD (Post Traumatic Stress Disorder), CTE (Chronic Traumatic ...

Mar 25 2022

Halberd Corporation Brief Overview

By Halberd|2022-03-25T09:57:20-04:00March 25th, 2022|Featured, News|Comments Off on Halberd Corporation Brief Overview

Halberd Corporation Brief Overview Halberd Corporation was re-formed in May 2020. Noting that Halberd’s unique extracorporeal technological approach is adaptable to many disease states, Halberd’s team of professionals employed its skills, resources and focus to concentrate on developing treatments against some of the world’s more persistent diseases, such as, Alzheimer’s Disease, PTSD, ...

Oct 19 2021

Interleukin-6 induces impairment in human subcutaneous adipogenesis in obesity-associated insulin resistance

By Halberd|2021-10-19T20:51:31-04:00October 19th, 2021|Press Releases|Comments Off on Interleukin-6 induces impairment in human subcutaneous adipogenesis in obesity-associated insulin resistance

Abstract Aims/hypothesis A subset of obese individuals remains insulin sensitive by mechanisms as yet unclear. The hypothesis that maintenance of normal subcutaneous (SC) adipogenesis accounts, at least partially, for this protective phenotype and whether it can be abrogated by chronic exposure to IL-6 was investigated. Methods Adipose tissue biopsies were collected from insulin-sensitive (IS) and ...

Oct 19 2021

Insulin Resistance Associated To Obesity: The Link TNF-Alpha

By Halberd|2021-10-19T20:43:06-04:00October 19th, 2021|Press Releases|Comments Off on Insulin Resistance Associated To Obesity: The Link TNF-Alpha

Iria Nieto-Vazquez, Sonia Fernández-Veledo, David K. Krämer,Rocio Vila-Bedmar, Lucia Garcia-Guerra & Margarita Lorenzo Abstract Adipose tissue secretes proteins which may influence insulin sensitivity. Among them, tumour necrosis factor (TNF)-alpha has been proposed as a link between obesity and insulin resistance because TNF-alpha is overexpressed in adipose tissue from obese animals and humans, and obese mice ...

Oct 19 2021

Fat-fighting Nanoparticles New Drug-Delivery Approach Holds Potential For Treating Obesity

By Halberd|2021-10-19T20:34:25-04:00October 19th, 2021|Press Releases|Comments Off on Fat-fighting Nanoparticles New Drug-Delivery Approach Holds Potential For Treating Obesity

SOURCE: https://news.mit.edu/2016/fat-fighting-nanoparticles-obesity-0502 "Researchers at MIT and Brigham and Women’s Hospital have developed nanoparticles that can deliver antiobesity drugs directly to fat tissue. Overweight mice treated with these nanoparticles lost 10 percent of their body weight over 25 days, without showing any negative side effects. The drugs work by transforming white adipose tissue, which is ...

Oct 19 2021

Association of Interleukin-6 Haplotypes, Obesity, and Metabolic Abnormalities in a Population of Central Mexico

By Halberd|2021-10-19T20:31:40-04:00October 19th, 2021|Press Releases|Comments Off on Association of Interleukin-6 Haplotypes, Obesity, and Metabolic Abnormalities in a Population of Central Mexico

Abstract Objective: We undertook this study to determine the relationship among -174G>C and 598G>A polymorphisms in the promoter region of interleukin-6, obesity, and metabolic abnormalities in subjects from central Mexico. Methods: Included in the study were 150 subjects who were not first-degree relatives of patients with diabetes and 106 blood samples from the general population. ...

Oct 19 2021

Alpha 1-Antitrypsin. A Novel Biomarker for Obesity in Humans

By Halberd|2021-10-19T20:41:18-04:00October 19th, 2021|Press Releases|Comments Off on Alpha 1-Antitrypsin. A Novel Biomarker for Obesity in Humans

Abstract Objective: To investigate the relationship between alpha 1-antitrypsin (A1AT), adiponectin, leptin, blood glucose, and insulin protein levels in human serum and obesity. Methods: Forty-eight subjects with normal blood glucose levels and average age of 32.4+/-5.1 years were enrolled in this study. The study took place in the Reproductive Center, The Second Hospital of Jilin University, Changchun, ...

Jan 28 2021

Halberd Corporation Discusses Qualitative & Quantitative Diagnostic Methodology for Detecting COVID-19 Antibodies and Antigens with The Stock Day Podcast

By Halberd|2021-01-28T08:45:25-05:00January 28th, 2021|Featured, Investor News, News|0 Comments

Halberd Corporation Discusses Qualitative & Quantitative Diagnostic Methodology for Detecting COVID-19 Antibodies and Antigens with The Stock Day Podcast Phoenix, AZ January 28th, 2021 (Newsfile Corp.) -- The Stock Day Podcast welcomed Halberd Corporation (OTC Pink: HALB) ("the Company"), a company with a patented extracorporeal treatment applicable to many hard-to-cure blood-borne and neurological diseases, ...

Halberd

About Halberd